Now live: Pro — the full 13F research suite for serious investorsSee pricing →
M28 Capital Management LP

Q3 2024 · 13F-HR

M28 Capital Management LPholdings as filed

Filed 2024-11-12 · accession 0000902664-24-006434

$91.0M
Reported value
11
Positions
2024-09-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
Y95308105WVEWAVE LIFE SCIENCES LTD$50.5M55.5%6,164,548CommonSOLE
00534A102IVVDINVIVYD INC$9.4M10.4%9,248,250CommonSOLE
77313F106RCKTROCKET PHARMACEUTICALS INC$7.1M7.83%385,680CommonSOLE
35168W103GUTSFRACTYL HEALTH INC$4.7M5.16%1,856,117CommonSOLE
88322Q108TGTXTG THERAPEUTICS INC$3.8M4.15%161,600CommonSOLE
85205L107SWTXUSDSPRINGWORKS THERAPEUTICS INC$3.5M3.89%110,400CommonSOLE
82686Q101SLNSILENCE THERAPEUTICS PLC$3.4M3.70%185,100CommonSOLE
10806X102BBIOBRIDGEBIO PHARMA INC$3.1M3.39%121,200CommonSOLE
231269309CRISCURIS INC$2.3M2.50%421,951CommonSOLE
N71542109PRQRPROQR THRAPEUTICS N V$1.9M2.04%1,019,498CommonSOLE
04280A100ARWRARROWHEAD PHARMACEUTICALS IN$1.3M1.43%67,400CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.